InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Wednesday. The firm issued a sell rating on the stock.

InspireMD Price Performance

NSPR stock opened at $1.85 on Wednesday. The company’s 50 day simple moving average is $2.39 and its 200-day simple moving average is $2.68. InspireMD has a 12 month low of $1.03 and a 12 month high of $3.85. The firm has a market capitalization of $43.29 million, a PE ratio of -1.71 and a beta of 0.83.

InspireMD (NYSE:NSPR) last announced its earnings results on Wednesday, March 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The firm had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same quarter in the prior year, the firm earned ($0.60) EPS. As a group, sell-side analysts anticipate that InspireMD will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Avestar Capital LLC acquired a new stake in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $65,000. Avestar Capital LLC owned 0.09% of InspireMD as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.